Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential
The FASEB Journal · 15.09.2026 · 40 (17)
DOI: 10.1096/fj.202602532r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 31.08.2026. Verfasst von Urooj Yousaf Virk und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia. Hauptthemen laut MEDLINE: Superantigens, Neoplasms, Immunotherapy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer immunotherapy has reshaped modern oncology by enabling the immune system to recognize and eliminate malignant cells. However, many solid tumors still respond poorly because of weak T‐cell activation and an immunosuppressive tumor microenvironment. Bacterial superantigens (SAgs) represent a unique class of immunomodulatory proteins capable of overcoming these limitations through direct activation of large T‐cell populations. Unlike conventional antigens, superantigens bypass classical antigen processing by simultaneously binding major histocompatibility complex class II molecules and T‐cell receptor Vβ domains, triggering rapid cytokine release and extensive immune activation. Although this potent mechanism has historically been associated with severe systemic toxicity, recent advances in protein engineering and targeted delivery have renewed interest in their therapeutic potential. This review discusses the structural and immunological basis of superantigen activity and highlights emerging strategies designed to improve tumor specificity and safety, including engineered low‐toxicity variants, antibody‐superantigen fusion proteins, nanoparticle‐based delivery systems, and tumor‐targeted constructs. We further examine how superantigens reshape the tumor microenvironment and synergize with immune checkpoint blockade, adoptive cell therapies, and other T‐cell‐redirecting approaches. Together, these advances position engineered superantigens as promising immune‐amplifying platforms with the potential to complement existing cancer immunotherapies and improve responses in poorly immunogenic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia.
ORCID-Profile: Urooj Yousaf Virk
Zitieren
APA
Virk, U. Y., Malik, H. A., Anwer, M., Wilson, J., Rahi, M. S., & Wei, M. Q. (2026). Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential. The FASEB Journal, 40(17). https://doi.org/10.1096/fj.202602532r
Vancouver
Virk UY, Malik HA, Anwer M, Wilson J, Rahi MS, Wei MQ. Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential. The FASEB Journal. 2026;40(17). doi:10.1096/fj.202602532r
BibTeX
@article{Virk2026,
author = {Virk, Urooj Yousaf and Malik, Hafiza Aasia and Anwer, Muneera and Wilson, Jennifer and Rahi, Md Sifat and Wei, Ming Q},
title = {Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {17},
doi = {10.1096/fj.202602532r}
}
EUVIMED